Title: Cardiovascular health in early pregnancy and circulating biomarkers of placental health and function

Andrea C. Kozai, PhD: Department of Epidemiology, University of Pittsburgh School of Public Health

Bethany Barone Gibbs, PhD: Department of Epidemiology and Biostatistics, West Virginia University School of Public Health

Samuel Parry, MD: Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine

Sadiya S. Khan, MD, MSc: Department of Medicine Northwestern University Feinberg School of Medicine

William Grobman, MD, MBA: Department of Obstetrics and Gynecology, Brown University School of Medicine

Lisa D. Levine, MD, MSCE: Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine

Rebecca McNeil, PhD: Research Triangle International

David M. Haas, MD, MS: Department of Obstetrics & Gynecology Indiana University School of Medicine

Jessica L. Pippen, MD: The MetroHealth System, Case Western Reserve University

Robert M. Silver, MD: Department of Obstetrics and Gynecology, University of Utah

Janet M. Catov, PhD: Department of Epidemiology, Department of Obstetrics and Gynecology, University of Pittsburgh

Corresponding author:
Andrea C. Kozai
130 N. Bellefield Ave
Pittsburgh, PA 15213
andrea.kozai@pitt.edu

Abstract

Background

Maternal cardiovascular health (CVH) and placental health are related to pregnancy outcomes, yet how early pregnancy CVH affects placentation is not well characterized. The objective of this study was to determine associations between CVH and concentrations of placental proteins.

Methods

Participants from the nuMoM2b prospective cohort were included (n=2188). Maternal CVH was defined three ways: (1) composite scores using 6 components measured in the 1st trimester (four behavioral components of physical activity, diet, sleep duration, and smoking, and the health factors of blood pressure and body mass index); (2) latent classes of the four behavioral components; and (3) individual health behaviors. Linear regression associated composite CVH, latent classes, and individual health behaviors with 1st and 2nd trimester circulating markers of placental growth and development (pregnancy-associated plasma protein A, PAPP-A), pro-angiogenic (vascular endothelial growth factor, VEGF; placental growth factor, PlGF), and anti-angiogenic factors (soluble FMS-like tyrosine kinase 1, sFlt-1; soluble endoglin, sEng).

Results and Conclusions

More favorable composite CVH was associated with higher PAPP-A (representing better 1st trimester placental growth and development) and lower VEGF and higher sEng (representing an anti-angiogenic 1st trimester profile). Higher levels of physical activity were associated with lower 2nd trimester PAPP-A and higher 1st trimester VEGF and lower sFlt-1 (pro-angiogenic). In the four groups identified with latent class analysis (Healthy Behaviors, Active with Poor Diet, Inactive with Poor Diet, and Less Healthy Behaviors), first trimester sFlt-1 was lower in the Healthy Behaviors group compared to Inactive with Poor Diet group. Modifiable aspects of CVH in early pregnancy are related to placental health and function and may be useful targets for intervention.

Keywords: Life's Essential 8; nuMoM2b; placental growth and development; angiogenic balance; maternal fetal health; health behaviors

Non-standard Abbreviations and Acronyms

APO – Adverse pregnancy outcomes

BMI – Body mass index

CVD – Cardiovascular disease

CVH – Cardiovascular health

HEI – Healthy Eating Index

METs – Metabolic equivalents of the task

MVPA – Moderate-to-vigorous physical activity

nuMoM2b – Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be

PAPP-A – Pregnancy-associated plasma protein A

PlGF – Placental growth factor

PTB – Preterm birth

sEng – Soluble endoglin

sFlt-1 – Soluble FMS-like tyrosine kinase 1

SGA – Small for gestational age

VEGF – Vascular endothelial growth factor

Clinical Perspective

What is New?

- Combinations of modifiable health behaviors in early pregnancy are related to circulating markers of placental development and function.
- These associations varied according to trimester of placental biomarker assessment, suggesting that patterns across gestation may be informative.
- More physical activity in the 1st trimester was associated with lower PAPP-A concentrations in the 2nd trimester without a concurrent increase in the rate of adverse outcomes.

What are the Clinical Implications?

- This study suggests that more favorable cardiovascular health in early pregnancy may be related to differences in placental health and function as reflected by higher concentrations of PAPP-A.
- One mechanism of the benefits of physical activity in early pregnancy may be through improved angiogenic/anti-angiogenic balance as measured by VEGF and sFlt-1 in the 1st trimester.

Introduction

Pregnancy is a cardiovascular stress test, during which maternal cardiovascular physiology undergoes dramatic changes.[1–3] Many adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, small-for-gestational-age, and preterm birth are associated with poor placental implantation and development[4–7], but the mechanisms

connecting maternal cardiovascular health, poor placental development, and APOs are still being elucidated.[8] Risk factors for APOs are similar to those for cardiovascular disease (CVD), indicating shared pathophysiology may exist.[2] Robust early placentation is key to pregnancy health[9,10], but early detection of poor placentation is difficult to ascertain and evidence is needed to identify those at increased risk who may benefit from early intervention, particularly among pregnant people with no prior pregnancy history. Therefore, it is important to identify how components of cardiovascular health (CVH) are associated with placental development.

In recognition of the importance of preventing risk factors for CVD, the American Heart Association has set scoring standards for several key components of "ideal" CVH, including health behaviors (physical activity, diet, smoking, and sleep duration) and health factors (blood pressure, glucose, lipids, and body mass index).[11,12] Higher scores are associated with lower incidence of CVD in a variety of populations.[13–15] Evidence suggests that higher (more favorable) CVH scores in pregnancy are associated with lower risk of preeclampsia and other adverse outcomes[16], but the relationship between early-pregnancy CVH and circulating biomarkers of placental health and function is not well-established.

The health behavior components are of particular interest in pregnancy given that non-pharmacologic interventions are often preferred by providers and pregnant individuals. Moderate-to-vigorous physical activity (MVPA) has a beneficial relationship with circulating angiogenic biomarkers outside of pregnancy[17–20], but the pregnancy literature is more limited and is largely confined to late-pregnancy measures. Adequate sleep and diet have been associated with pregnancy health overall[21–23], but data associating these health behaviors with markers of placental health and function are scant. And while these individual health behaviors exhibit some associations with pregnancy health, it is unknown whether the engagement in different combinations of these behaviors impacts placental health and function.

The placenta is a dynamic organ that undergoes phases of development depending on the gestational age of the pregnancy.[24,25] As such, circulating biomarkers of placental health and function may be differentially impacted by behavioral components of CVH depending on the trimester in which the behavior takes place. Several biomarkers of placental health and function have been associated with a greater chance of APOs. These include pregnancy-associated plasma protein A (PAPP-A), which is secreted by the placental syncytiotrophoblast and is a biomarker of placental growth and development, as well as the angiogenic factors of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) and the anti-angiogenic factors of soluble FMS-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng). Some evidence shows that aspects of CVH in pregnancy may be associated with biomarkers of placental growth and development and angiogenic balance[20,26], and higher early-pregnancy BMI has been shown to be associated with less favorable 1st and 2nd trimester concentrations of sFlt-1.[27] It is not yet understood whether the full 1st trimester composite Life's Essential 8 CVH score, individual health behavior components, or different combinations of health behaviors in early pregnancy are related to placental biomarker concentrations in early- to mid-pregnancy. These questions are important to elucidate the mechanistic links between CVH and APOs and to determine the time frame across which early-pregnancy health behaviors may influence placental development and function.

The purpose of this study was to examine whether 1st trimester composite CVH scores, individual health behavior scores, and combinations of the health behavior components were associated with circulating maternal concentrations of biomarkers of placental growth and development and angiogenic balance in the 1st or 2nd trimesters of pregnancy. We hypothesized that more ideal CVH and adherence to healthier behaviors in the 1st trimester would be associated with more favorable biomarker concentrations including higher PAPP-A, indicating

more robust placental growth and development, higher pro-angiogenic VEGF and PlGF, and lower antiangiogenic sFlt-1 and sEng in the 1st and 2nd trimesters.

Methods

Sample

A subset of participants from the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers to Be (nuMoM2b) prospective cohort comprised the sample for this study. Full methods for the cohort have been published previously.[28] Briefly, nulliparous pregnant people with a singleton gestation were recruited in early pregnancy (6^0-13^6 weeks gestation) and assessed three times throughout pregnancy (baseline, 16^0-21^6 weeks gestation and 22^0-29^6 weeks gestation) and at delivery. Assessments included questionnaires, clinical measurements, and blood draws. Ethical approval was obtained at each clinical site and participants provided informed consent prior to data collection. Biomarker assays were conducted on 1st and 2nd trimester samples using a case-subcohort design drawing from individuals who delivered after 20 weeks of gestation and provided sufficient serum.[29] All cases of APO (preterm birth, preeclampsia, stillbirth, and/or small-for-gestational-age birth), as well as a random sample of 12% of the remaining individuals with uncomplicated, term deliveries, were included. The sampling proportion of 12% was determined by the funds available for assays.

Cardiovascular Health Score

Each component of the CVH score was assessed in the 1st trimester at the baseline visit and assigned a score on a scale of 0-100 according to the Life's Essential 8 scoring algorithm, in which higher scores indicate more favorable health.[12] The full scoring algorithm can be found in **Table S1**.

Physical activity was assessed via a self-report questionnaire, in which participants identified frequency, duration, and type of activities over the past 4 weeks. Average minutes per week of moderate (3.0-5.9 metabolic equivalents of task [METs]) and vigorous (≥6.0 METs) leisure time physical activity were calculated based on corresponding MET values from the Compendium of Physical Activities[30], and weekly duration of MVPA as it pertains to U.S. federal guidelines was calculated as minutes of moderate plus 2 x minutes of vigorous activity.[31] CVH scores ranged from 0 (no weekly MVPA) to 100 (≥150 minutes/week MVPA) with intermediate scores for values between 0-150 minutes/week. Physical activity was additionally categorized into none (no weekly MVPA), insufficient (1-149 minutes/week MVPA), sufficient (150-299 minutes/week MVPA), and high (300+ minutes/week MVPA).

The Healthy Eating Index (HEI) score was used to assess diet quality and was determined using a modified Block Food Frequency Questionnaire[32,33] with reference to the 3-month period immediately preceding conception. CVH scores were based on percentiles of HEI scores in the full nuMoM2b sample; for example, 0 points corresponded to HEI <25th percentile, while 100 points corresponded to HEI ≥95th percentile.

Self-reported weekday and weekend hours of nightly sleep were used to determine sleep duration. Weighted averages were calculated to account for differences between weekday and weekend sleep duration, and CVH scores were assigned based on the U-shaped association between sleep duration and cardiovascular health (i.e., both low and high sleep durations are adverse).

Participants self-reported combustible tobacco use and exposure to secondhand smoke in the home. CVH scoring for smoking was adapted from the standard scoring algorithm (see **Table S1**). A score of 0 indicated current smoking during pregnancy, while a score of 100 indicated never smoking tobacco; intermediate scores were assigned for former smokers. 20

points were subtracted in cases of exposure to secondhand smoke in the home for all except current smokers.

Blood pressure, height, and weight were measured in person by research personnel using standardized techniques. Body mass index (BMI) was calculated from height and weight measures in kg/m^2. The standard scoring algorithms for blood pressure and BMI were applied to calculate component scores. Blood draws were obtained in a non-fasted state, so the lipid and glucose components of the composite CVH score were excluded from this analysis.

The composite CVH score was derived by averaging the scores of the 6 available components: physical activity, diet, sleep, smoking, blood pressure, and BMI.

Placental blood analytes

Full methodology of the biomarker assays have been published previously[29]; in brief, blood serum samples collected at the study visits in the 1st and 2nd trimester were stored at -70° C, then assayed with enzyme-linked immunosorbent assay (sEng), electrochemiluminescence assay (VEGF and sFlt-1), and lanthanide-based time-resolved fluorometry (PlGF and PAPP-A). Concentrations below the limits of detection were assigned values equal to half the lower limit, while those above the upper limit were assigned a value equal to the upper limit.

Covariates

Demographic information including age, race/ethnicity, educational attainment, income, and health insurance status were self-reported via questionnaire at the baseline visit. At the second visit, participants completed the Krieger Discrimination Scale[34] to assess experiences with racial discrimination and the Connor-Davidson Resilience Scale[35] to assess resilience.

Statistical Analyses

Latent (unobserved) classes of adherence to combinations of the four health behaviors were constructed empirically using the "gsem" command in Stata, which can compute the

models using continuous values. Models were built using 1st trimester CVH scores on a scale of 0-100 for each of the four health behaviors (physical activity, diet, sleep duration, and smoking) based on the full nuMoM2b sample (N=10,038), and the best-fitting model was selected based on values of Akaike/Bayesian Information Criterion, sample size in each class, and model interpretability; posterior probabilities were also assessed.

Distributions of placental blood biomarkers were examined for normality and log-transformed if appropriate. Descriptive characteristics were compared among behavioral latent classes using Chi-square tests for categorical variables and analysis of variance for continuous variables.

Associations between composite CVH scores, behavioral latent classes, and individual health behavior scores with each placental blood biomarker were examined using linear regression. Two sets of analyses were conducted. First, a cross-sectional analysis examined the association between 1st trimester exposures (composite CVH scores, behavioral latent classes, and each individual health behavior) and 1st trimester serum biomarker concentrations. Next, a longitudinal analysis examining the association between 1st trimester CVH exposures and 2nd trimester biomarker concentrations was performed. Scatterplot visualizations of the associations between physical activity scores and the biomarkers suggested a nonlinear association, so physical activity was analyzed categorically (none, insufficient, sufficient, and high); diet, sleep duration, and smoking were analyzed as continuous CVH component scores.

Sampling weights were added to all analyses to account for the overrepresentation of APO in the placental analyte subsample, wherein each observation was weighted based on the inverse of the sampling proportion (i.e., a weight of 1 was applied to cases of APO, while a weight of 8.48 was applied to non-APO observations). All linear regression models were adjusted for gestational age at the time of the blood draw, and longitudinal analyses were

additionally adjusted for 1st trimester biomarker concentrations. These minimally adjusted models were further adjusted for demographic characteristics, BMI (latent class and individual health behavior analyses only), perceived racial discrimination, and resilience in a backwards stepwise approach in which covariate associations with a p-value <0.2 were retained in the fully adjusted model. All analyses were conducted in Stata SE version 18 (StataCorp, College Station, TX) and significant associations were accepted at p<0.01 to account for multiple comparisons.

Results

Participants

Of the original 10,038 nuMoM2b participants, 2,188 were included in this analysis (**Figure 1**). Mean baseline age was 26.9±5.8 years and mean BMI was 26.9±6.8 kg/m^2. Prior to applying sampling weights, those included in this analysis had significantly higher BMI, were more likely to report non-Hispanic Black race, less education, lower perceived racial discrimination, and, by design, more likely to experience an APO than the full cohort. After sample weights were applied, participants included in this analysis had similar rates of APO but had significantly lower BMI and were more likely to report non-Hispanic White race, lower perceived racial discrimination, and use of commercial insurance than the full cohort (**Table S2**).



Figure 1. CONSORT diagram of included and excluded participants. nuMoM2b: Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be; GA: gestational age; SGA: small for gestational age; PTB: preterm (<37 weeks GA) birth.

Composite CVH Scores and Health Behavior Latent Classes

The mean composite CVH score in this sample was 71.1 ± 15.4 points. Thirty percent of participants achieved a "high" CVH score (≥80 points), 56% had "moderate" CVH (score of 50-79 points), and 14% had "low" CVH (<50 points) as defined by the American Heart Association.[12]

For the behavioral latent class analysis, the model fit criteria (**Table S3**) indicated a 4-class solution was the most appropriate: Healthy Behaviors (n=756 [34.6%]), Active with Poor Diet (n=449 [20.5%]), Inactive with Poor Diet (n=717 [32.8%], and Less Healthy Behaviors (n=265 [12.1%]) **(Figure 2)**.



Figure 2. Weighted mean (SD) cardiovascular health (CVH) scores for each health behavior component in each latent class. Higher score indicates more ideal CVH; scores <50 are "poor" CVH; 50-79 are "moderate" CVH, and scores ≥80 are "high" CVH as indicated by markers on the y-axis.

Participants who were older, with a lower BMI, non-Hispanic White, and who had more education, higher income, or commercial insurance were significantly more likely to belong to the Healthy Behaviors class compared to the other classes. Furthermore, the composite CVH score was significantly higher and the rate of APO was significantly lower in the Healthy Behaviors class compared to the other classes in this sample **(Table 1)**. Absolute concentrations of each placental biomarker by latent class in each trimester can be found in **Table S4**.

Table 1. Descriptive characteristics and of participants by latent classes. Results presented as weighted mean ± SD, weighted median (interquartile range), or frequency (weighted percentage) as appropriate. Significance accepted at p<0.01. Perceived racial discrimination scores from Krieger discrimination scale: None: 0; Moderate: 1-2; High: 3+. Resilience scores on a scale from 0-100. BMI: body mass index; CVH: cardiovascular health; APO: adverse pregnancy outcome.

	Healthy Behaviors (n=756)	Active with Poor Diet (n=449)	Inactive with Poor Diet (n=718)	Less Healthy Behaviors (n=265)	p-value
Maternal age (years)	28.8 ± 4.9	26.5 ± 6.0	25.8 ± 5.5	23.9 ± 5.7	**<0.001**
BMI (kg/m^2)	25.0 ± 4.7	26.9 ± 6.9	26.7 ± 6.6	26.3 ± 7.1	**<0.001**
Maternal race					**<0.001**
Asian	41 (4%)	8 (2%)	21 (3%)	3 (1%)	
Black non-Hispanic	51 (6%)	83 (14%)	146 (16%)	72 (25%)	
Hispanic	67 (8%)	80 (19%)	151 (21%)	62 (30%)	
White non-Hispanic	564 (77%)	252 (62%)	358 (56%)	103 (35%)	
Other	33 (5%)	26 (4%)	41 (4%)	25 (9%)	
Educational Attainment					**<0.001**
Less than high school	12 (1%)	57 (11%)	97 (12%)	52 (19%)	
Completed high school or GED	25 (3%)	74 (15%)	131 (18%)	59 (26%)	
Some college	86 (12%)	107 (20%)	187 (25%)	66 (23%)	
Associate or technical degree	68 (9%)	48 (10%)	89 (11%)	28 (6%)	
Completed college	284 (37%)	96 (26%)	128 (20%)	33 (14%)	
Degree work beyond college	281 (37%)	67 (18%)	85 (14%)	27 (12%)	
Percentage of Federal Poverty Level					**<0.001**
<100%	43 (6%)	81 (19%)	116 (21%)	58 (32%)	
100-200%	63 (9%)	65 (13%)	96 (18%)	31 (18%)	
>200%	584 (84%)	197 (68%)	301 (62%)	82 (50%)	
Insurance payor					**<0.001**
Commercial	494 (68%)	207 (53%)	336 (51%)	91 (34%)	
Medicare/Medicaid	54 (6%)	158 (26%)	269 (34%)	138 (53%)	
Military/Other	9 (1%)	9 (1%)	6 (1%)	7 (2%)	
Two or more sources	180 (23%)	53 (15%)	84 (13%)	20 (7%)	
None (personal income)	15 (2%)	17 (5%)	12 (1%)	4 (3%)	
Perceived racial discrimination					**0.002**
None	598 (79%)	317 (72%)	525 (76%)	181 (67%)	
Moderate	110 (15%)	99 (19%)	132 (17%)	56 (22%)	
High	48 (6%)	33 (9%)	61 (7%)	28 (11%)	
Resilience	82.0 ± 10.79	78.9 ± 11.81	77.7 ± 12.26	78.7 ± 12.97	**<0.001**
Composite CVH score	84.2 ± 8.49	69.5 ± 10.46	60.1 ± 11.71	56.9 ± 12.91	**<0.001**
APO	412 (12%)	303 (20%)	454 (17%)	180 (20%)	**<0.001**

Placental growth and development: PAPP-A

A higher (more favorable) 1st trimester composite CVH score was associated with higher (more favorable) 1st trimester PAPP-A concentration (**Table 2**, p<0.001); this association was not detected in longitudinal analysis evaluating the association of 1st trimester composite CVH score with 2nd trimester PAPP-A concentrations. No significant associations were found between the behavioral latent classes and PAPP-A concentrations in either cross-sectional or longitudinal analyses (**Tables S5 & S6**).

Table 2. Association between 1st trimester cardiovascular health (CVH) score and placental biomarkers in the 1st and 2nd trimesters. ß coefficients show the change in biomarker concentration per 10-point increase in CVH score. Model 1 is adjusted for gestational age at the blood draw (1st and 2nd trimester analyses) and 1st trimester biomarker concentration (2nd trimester analyses only). Model 2 is additionally adjusted for maternal age, race, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

	ß coefficient (95% CI) per 10-points CVH score Model 1	**p-value**	**ß coefficient (95% CI) per 10-points CVH score Model 2**	**p-value**
First trimester biomarkers				
PAPP-A (log mU/mL)	0.042 (0.023, 0.062)	**<0.001**	0.066 (0.040, 0.092)	**<0.001**
VEGF (log pg/mL)	-0.031 (-0.050, -0.013)	**0.001**	-0.038 (-0.049, -0.031)	**0.004**
PlGF (log pg/mL)	-0.006 (-0.017, 0.005)	0.259	0.003 (-0.011, 0.017)	0.648
sFlt-1 (log pg/mL)	0.003 (-0.006, 0.011)	0.529	0.011 (0.0001, 0.021)	0.048
sEng (ng/mL)	0.232 (0.171, 0.292)	**<0.001**	0.218 (0.144, 0.292)	**<0.001**
Second trimester biomarkers				
PAPP-A (log mU/mL)	0.001 (-0.009, 0.012)	0.805	0.013 (0.0001, 0.025)	0.049
VEGF (log pg/mL)	-0.004 (-0.017, 0.008)	0.504	-0.004 (-0.019, 0.012)	0.645
PlGF (log pg/mL)	0.005 (-0.006, 0.016)	0.370	0.006 (-0.006, 0.019)	0.327
sFlt-1 (log pg/mL)	-0.005 (-0.010, 0.0003)	0.064	-0.0003 (-0.007, 0.006)	0.933
sEng (ng/mL)	-0.014 (-0.051, 0.023)	0.460	-0.0006 (-0.052, 0.039)	0.791

Angiogenic balance: VEGF, PlGF, sFlt-1, sEng

A higher (healthier) 1st trimester composite CVH score was associated with a more anti-angiogenic 1st trimester biomarker profile, as reflected by a significantly lower concentration of VEGF and a significantly higher concentration of sEng in cross-sectional analyses (**Table 2**, p<0.001 for each).

Within the behavioral latent class analyses, a significant association was found between latent class and 1st trimester sFlt-1 concentration (**Figure 3**), in which those in the Inactive with Poor Diet class had a more anti-angiogenic profile, as characterized by higher sFlt-1 concentrations than those in the Healthy Behaviors class (p=0.008).

No longitudinal associations were detected between either composite CVH or the latent classes and 2nd trimester angiogenic biomarker concentrations (**Tables S5 & S6**).



Figure 3. Healthy behaviors latent class demonstrated significantly lower 1st trimester sFlt-1 concentration than the inactive with poor diet latent class, *p=0.008. sFlt-1: soluble FMS-like tyrosine kinase 1.

Individual Health Behaviors

Placental growth and development

In the longitudinal analysis, 1st trimester physical activity was associated with lower 2nd trimester concentration of PAPP-A, though a significantly lower proportion of those reporting sufficient weekly MVPA had an APO compared to those reporting no weekly MVPA (**Figure 4a**, p<0.01). Participants reporting no weekly MVPA had significantly higher PAPP-A than

those reporting insufficient, sufficient, or high MVPA (**Figure 4b**, p<0.001 for all). No significant associations were found in 1st trimester cross-sectional analysis for any of the individual health behaviors and 1st trimester PAPP-A concentration, and no significant longitudinal associations were found between component scores for the other health behaviors (diet, sleep, or smoking) and PAPP-A concentrations in the 2nd trimester (**Tables S7 & S8**).



Figure 4. Differences between physical activity categories, defined as: None = 0 minutes/week; Insufficient = 1-149 minutes per week; Sufficient = 150-299 minutes/week; High = ≥300 minutes/week. *Indicates p<0.01 **(a)** Significantly lower weighted rate of APO in those with sufficient weekly physical activity compared to none; **(b)** Any 1st trimester physical activity associated with lower 2nd trimester PAPP-A than none; **(c)** No weekly 1st trimester physical activity associated with lower 1st trimester VEGF than those with insufficient or high weekly physical activity (p<0.001), while those with sufficient weekly physical activity were non-significantly lower (p=0.02); **(d)** High weekly 1st trimester physical activity associated with lower 1st trimester sFlt-1 than no weekly physical activity. PAPP-A: pregnancy-associated plasma protein A; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor. Data presented as weighted percentages **(a)** or weighted means with 95% confidence intervals **(b-d)**.

Angiogenic balance

First trimester physical activity was associated with a pro-angiogenic 1st trimester profile: more weekly physical activity was associated with a higher VEGF concentration (**Figure 4c**, $p<0.001$ for insufficient and high MVPA compared to none), and high MVPA was associated with lower first trimester sFlt-1 concentration versus no weekly MVPA (**Figure 4d,** $p=0.003$). Longitudinal associations between 1st trimester physical activity categories and 2nd trimester concentrations of angiogenic biomarkers were nonsignificant, and no significant cross-sectional or longitudinal associations were found between component CVH scores for diet, sleep, or smoking and biomarkers of angiogenic balance (**Tables S7 & S8**).

Discussion

We found that composite CVH in early pregnancy, as well as individual and combined health behaviors, were associated with maternal concentrations of biomarkers of placental growth and development and angiogenic balance in nulliparous pregnant participants. Timing of these associations was important: 1st trimester CVH metrics (specifically, the composite CVH score and physical activity levels) were associated with both 1st and 2nd trimester placental growth and development via PAPP-A concentrations, while 1st trimester CVH metrics were only associated cross-sectionally with angiogenic balance via 1st trimester concentrations of VEGF, sFlt-1, and sEng. Furthermore, physical activity may be driving associations with these biomarkers as no associations were detected with the other individual health behaviors. These results suggest that modifiable aspects of early-pregnancy CVH such as physical activity may relate to placental health and function at varying points during the first half of pregnancy.

Placental growth and development

PAPP-A is a component of the insulin-like growth factor pathway.[36] PAPP-A concentrations increase across gestation in normal pregnancy[37,38] and display dysregulated

trajectories in cases of APOs.[39] In preeclampsia, 1st trimester PAPP-A is lower than normal, then climbs dramatically in the 3rd trimester to levels above normal.[40]

In line with our hypothesis, higher (more favorable) 1st trimester CVH scores were associated with higher 1st trimester circulating PAPP-A. As higher concentrations of this biomarker in early gestation are associated with better pregnancy outcomes, this finding suggests that higher early-pregnancy CVH may be related to more robust placentation and concomitant higher concentrations of PAPP-A. Whether early intervention to improve parameters of CVH can improve placentation through PAPP-A concentrations is worth future study.

In contrast, the association between greater 1st trimester physical activity and lower 2nd trimester concentrations of PAPP-A suggests that physical activity in early pregnancy is related to less robust placental growth and development by mid-pregnancy. This finding is in the opposite direction from our hypothesis, yet it is important to note that it did not appear to be pathological – participants who self-reported at least 150 minutes/week of 1st trimester MVPA had a significantly lower rate of APOs than those who self-reported no weekly MVPA. We speculate this finding may be due to the timing of the PAPP-A measurement. In the 2nd trimester, PAPP-A concentrations are similar between individuals who ultimately develop healthy and adverse pregnancy outcomes; low PAPP-A is adverse in the 1st trimester, but high PAPP-A is adverse in the 3rd trimester.[36,40] It is possible that the lower 2nd trimester PAPP-A concentrations we found in those engaging in physical activity may be indicative of physical activity eliciting a protective effect against high late-pregnancy concentrations. While very little is known regarding the regulation and control of PAPP-A during pregnancy, outside of pregnancy it is produced by several tissue types and is upregulated by inflammatory factors.[36] Given that one benefit of physical activity is reduced inflammation[41], it is possible that the lower

concentrations of 2nd trimester PAPP-A seen in those participants reporting higher physical activity is due to this mechanism. Additional research examining the mechanisms of this association is warranted.

Angiogenic balance

All significant associations examining 1st trimester CVH were with 1st trimester biomarkers of angiogenic balance, suggesting that while early-pregnancy CVH may play a role in angiogenesis in the first several weeks of gestation, it may not be directly related to mid-pregnancy angiogenic balance. However, prior work has demonstrated that components of CVH, themselves, are subject to change across pregnancy.[42] Therefore, as we did not examine changes in CVH across pregnancy, mid-pregnancy associations between health behaviors or composite CVH with biomarkers of angiogenic balance cannot be ruled out.

Interestingly, we found that healthier 1st trimester composite CVH scores were associated with a more anti-angiogenic 1st trimester profile, manifesting as lower concentrations of VEGF and higher concentrations of sEng. This was in the opposite direction as we hypothesized. VEGF is an angiogenic protein that is active in the early stages of placental development, and is also known to regulate vascular permeability.[43] Correlates of early pregnancy VEGF have not been extensively described; this finding will need to be replicated in future studies to confirm its validity. Further, higher concentrations of sEng in early- and mid-pregnancy are associated with higher risk for preeclampsia.[44–46] However, limited data suggest that certain components of CVH, namely BMI and smoking, are inversely related to sEng with higher concentrations in those with lower BMI and less smoking.[47] Prior work in this cohort found natriuretic peptide concentrations that would be considered adverse outside of pregnancy were, in fact, correlated with lower risk of APO and future maternal hyptertension;[48]

we speculate that sEng concentrations may be elevated in a similarly physiologically appropriate fashion in the first trimester, but this result must be confirmed in future studies.

In line with our hypothesis, we found that more self-reported 1st trimester physical activity was associated with a pro-angiogenic profile via higher VEGF and lower sFlt-1 concentrations in the 1st trimester. Higher VEGF concentrations have been detected in term placenta tissue in active versus inactive pregnant people;[49] our finding suggests this difference may be present as early as the 1st trimester. Additionally, we confirmed the findings of Whorton, et al.[20], who found significantly lower sFlt-1 concentrations in those above versus below 150 min/week MVPA. Our results expand on this finding, as we demonstrated that the lowest concentration of sFlt-1 was seen in those reporting ≥300 min/week MVPA and that those reporting 150-299 min/week were not significantly different from those reporting no weekly MVPA. This suggests that physical activity may indeed be a potential mechanism to reduce the antiangiogenic sFlt-1 concentration in early pregnancy[20], but it may require high volumes of MVPA to reach this target.

A similar sFlt-1 result was found in the latent class analysis, suggesting that physical activity was likely driving the differences found between latent classes for this biomarker. Only the Inactive with Poor Diet class demonstrated significantly higher sFlt-1 concentration than the Healthy Behaviors class, despite the Less Healthy Behaviors class displaying the lowest mean composite CVH score. This indicates that low physical activity, the unique feature of the Inactive with Poor Diet class, may have been the predominant contributor to this finding.

Strengths and Limitations

This study is bolstered by several strengths. We used a diverse national cohort of nulliparous individuals, in which robust data were collected across pregnancy. This allowed us to examine both cross-sectional and longitudinal associations between CVH and placental

biomarkers in the 1st and 2nd trimesters, which is of particular importance given the dynamic nature of placental development throughout pregnancy. This is also the first examination to our knowledge of the ways in which pregnant individuals engage in health behaviors in combination, which provides novel data that can be translated into behavioral interventions.

Certain limitations are acknowledged. The sample for this analysis was comprised of all cases of APO and a random sample of remaining participants with uncomplicated full-term pregnancies from the parent study. While we used sampling weights to account for this, significant differences remained between our weighted sample and the full cohort. Multiple comparisons may have led to a Type I error and paradoxical results suggest these findings should be interpreted with caution, though we used an *a priori* cutoff of $p<0.01$ to mitigate this risk. By only analyzing those whose pregnancies continued beyond 20 weeks of gestation our results may be impacted by survivor's bias. Health behaviors were all self-reported which may have introduced recall bias, although participants were not aware of biomarker concentrations at the time of behavior recall so non-random bias should be minimal. The diet assessment referenced the 3 months prior to conception and may not have been representative of 1st trimester dietary intake. Finally, we did not adjust for medications; while it is possible that aspirin therapy could have impacted our results, prior analysis in this cohort found less than 2% of participants reported aspirin use during their pregnancy.[50]

Conclusions

This study found that healthier 1st trimester CVH was associated with higher 1st trimester circulating PAPP-A (suggestive of more robust early placentation) and with a more anti-angiogenic 1st trimester profile of lower VEGF and higher sEng. Furthermore, physical activity alone and latent classes with higher physical activity were consistently associated with

biomarkers of placental health and function. These findings suggest that while 1st trimester composite CVH may not be directly related to 2nd trimester biomarker concentrations, physical activity in the 1st trimester may have a distinct and lasting association. These results suggest the importance of initiating behavioral interventions in the 1st trimester to improve pregnancy health.

Sources of Funding: The nuMoM2b project was supported by grant funding from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD): U10 HD063036; U10 HD063072; U10 HD063047; U10 HD063037; U10 HD063041; U10 HD063020; U10 HD063046; U10 HD063048; and U10 HD063053. In addition, support was provided by Clinical and Translational Science Institutes: UL1TR001108 and UL1TR000153. The nuMoM2b Heart Health Study was supported by cooperative agreement funding from the National Heart, Lung, and Blood Institute and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development: U10-HL119991; U10-HL119989; U10-HL120034; U10-HL119990; U10-HL120006; U10-HL119992; U10-HL120019; U10-HL119993; U10-HL120018, and U01HL145358; with supplemental support to NHLBI U10-HL119991 from the Office of Research on Women's Health and the Office of Disease Prevention and to NHLBI U01HL145358 from the Office of Research on Women's Health; and the National Center for Advancing Translational Sciences through UL-1-TR000124, UL-1-TR000153, UL-1-TR000439, and UL-1-TR001108; and the Barbra Streisand Women's Cardiovascular Research and Education Program, and the Erika J. Glazer Women's Heart Research Initiative, Cedars-Sinai Medical Center, Los Angeles. The Sedentary Behavior and Cardiovascular Health in Young Women ancillary study is supported by R01HL158652. ACK is supported under T32HL083825.

References

1. Brislane Á, Steinback CD, Davenport MH. The 9-Month Stress Test: Pregnancy and Exercise—Similarities and Interactions. *Canadian Journal of Cardiology*. 2021;37(12):2014-2025. doi:10.1016/j.cjca.2021.09.003

2. Khan SS, Cameron NA, Lindley KJ. Pregnancy as an Early Cardiovascular Moment: Peripartum Cardiovascular Health. *Circulation Research*. 2023;132(12):1584-1606. doi:10.1161/CIRCRESAHA.123.322001

3. Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes. *Journal of the American College of Cardiology*. 2019;73(16):2106-2116. doi:10.1016/j.jacc.2018.12.092

4. Parks WT, Catov JM. The Placenta as a Window to Maternal Vascular Health. *Obstet Gynecol Clin N Am*. 2020;47:17-28.

5. Schmella MJ, Assibey-Mensah V, Parks WT, et al. Plasma concentrations of soluble endoglin in the maternal circulation are associated with maternal vascular malperfusion lesions in the placenta of women with preeclampsia. *Placenta*. 2019;78:29-35. doi:10.1016/j.placenta.2019.02.014

6. Cui L, Shu C, Liu Z, et al. The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia. *Pregnancy Hypertens*. 2018;13:127-132. doi:10.1016/j.preghy.2018.05.011

7. Romero R, Jung E, Chaiworapongsa T, et al. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. *American Journal of Obstetrics and Gynecology*. 2022;227(4):615.e1-615.e25. doi:10.1016/j.ajog.2022.04.015

8. McBride CA, Bernstein IM, Sybenga AB, McLean KC, Orfeo T, Bravo MC. Placental Maternal Vascular Malperfusion Is Associated with Prepregnancy and Early Pregnancy Maternal Cardiovascular and Thrombotic Profiles. *Serono Sym*. 2022;3(1):50-61. doi:10.3390/reprodmed3010006

9. Meekins JW, Pijnenborg R, Hanssens M, MCFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. *BJOG: An International Journal of Obstetrics & Gynaecology*. 1994;101(8):669-674. doi:10.1111/j.1471-0528.1994.tb13182.x

10. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. *Bmj*. 2019;366:l2381. doi:10.1136/bmj.l2381

11. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. *Circulation*. 2010;121(4):586-613. doi:10.1161/circulationaha.109.192703

12. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A

Presidential Advisory From the American Heart Association. *Circulation*. Published online 2022:101161CIR0000000000001078. doi:10.1161/cir.0000000000001078

13. Shpilsky D, Bambs C, Kip K, et al. Association between ideal cardiovascular health and markers of subclinical cardiovascular disease. *Clin Cardiol*. 2018;41(12):1593-1599. doi:10.1002/clc.23096

14. Nayor M, Enserro DM, Vasan RS, Xanthakis V. Cardiovascular Health Status and Incidence of Heart Failure in the Framingham Offspring Study. *Circulation Hear Fail*. 2018;9(1):e002416. doi:10.1161/circheartfailure.115.002416

15. Corlin L, Short MI, Vasan RS, Xanthakis V. Association of the Duration of Ideal Cardiovascular Health Through Adulthood With Cardiometabolic Outcomes and Mortality in the Framingham Offspring Study. *Jama Cardiol*. 2020;5(5):549-556. doi:10.1001/jamacardio.2020.0109

16. Perak AM, Lancki N, Kuang A, et al. Associations of gestational cardiovascular health with pregnancy outcomes: the Hyperglycemia and Adverse Pregnancy Outcome study. *Am J Obstet Gynecol*. 2021;224(2):210.e1-210.e17. doi:10.1016/j.ajog.2020.07.053

17. Hardy DB, Mu X, Marchiori KS, Mottola MF. Exercise in Pregnancy Increases Placental Angiogenin without Changes in Oxidative or Endoplasmic Reticulum Stress. *Medicine & Science in Sports & Exercise*. 2021;53(9):1846-1854. doi:10.1249/MSS.0000000000002647

18. Weissgerber TL, Davies GAL, Roberts JM. Modification of angiogenic factors by regular and acute exercise during pregnancy. *Journal of Applied Physiology*. 2010;108(5):1217-1223. doi:10.1152/japplphysiol.00008.2010

19. Gilbert JS, Banek CT, Bauer AJ, Gingery A, Dreyer HC. Placental and vascular adaptations to exercise training before and during pregnancy in the rat. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2012;303(5):R520-R526. doi:10.1152/ajpregu.00253.2012

20. Whorton AE, Pan AY, Palatnik A. Effects of physical activity on placental analytes in nulliparous persons. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2024;292:158-162. doi:10.1016/j.ejogrb.2023.11.018

21. Makarem N, Chau K, Miller EC, et al. Association of a Mediterranean Diet Pattern With Adverse Pregnancy Outcomes Among US Women. *JAMA Netw Open*. 2022;5(12):e2248165. doi:10.1001/jamanetworkopen.2022.48165

22. Miller C, Boushey C, Benny P, et al. Diet quality predicts hypertensive disorders of pregnancy in Asian and Pacific Islander Cohort. *Nutr Health*. Published online June 27, 2022:026010602211096. doi:10.1177/02601060221109668

23. Lu Q, Zhang X, Wang Y, et al. Sleep disturbances during pregnancy and adverse maternal and fetal outcomes: A systematic review and meta-analysis. *Sleep Medicine Reviews*. 2021;58:101436. doi:10.1016/j.smrv.2021.101436

24. Demir R, Kayisli UA, Cayli S, Huppertz B. Sequential Steps During Vasculogenesis and Angiogenesis in the Very Early Human Placenta. *Placenta*. 2006;27(6-7):535-539. doi:10.1016/j.placenta.2005.05.011

25. Verma U, Verma N. *The Placenta: Development, Function, and Diseases*. (Richard Nicholson, ed.). Nova Science Publishers, Inc; 2013.

26. Reijnders IF, Mulders AGMGJ, Windt M van der, Steegers EAP, Steegers-Theunissen RPM. The impact of periconceptional maternal lifestyle on clinical features and biomarkers of placental development and function: a systematic review. *Hum Reprod Update*. 2018;25(1):72-94. doi:10.1093/humupd/dmy037

27. Beck C, Allshouse A, Silver RM, et al. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers. *American Journal of Obstetrics & Gynecology MFM*. 2022;4(3):100614. doi:10.1016/j.ajogmf.2022.100614

28. Haas DM, Ehrenthal DB, Koch MA, et al. Pregnancy as a Window to Future Cardiovascular Health: Design and Implementation of the nuMoM2b Heart Health Study. *Am J Epidemiol*. 2016;183(6):519-530. doi:10.1093/aje/kwv309

29. Parry S, Carper BA, Grobman WA, et al. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients. *Am J Obstet Gynecol*. 2022;227(3):497.e1-497.e13. doi:10.1016/j.ajog.2022.03.064

30. Shephard RJ. 2011 Compendium of Physical Activities: A Second Update of Codes and MET Values. *Yearbook of Sports Medicine*. 2012;2012:126-127. doi:10.1016/j.yspm.2011.08.057

31. Services USD of H and H. *Physical Activity Guidelines for Americans, 2nd Edition*. U.S. Department of Health and Human Services; 2018.

32. Block G, Coyle LM, Hartman AM, Scoppa SM. Revision of Dietary Analysis Software for the Health Habits and History Questionnaire. *American Journal of Epidemiology*. 1994;139(12):1190-1196. doi:10.1093/oxfordjournals.aje.a116965

33. Parrott MS, Bodnar LM, Simhan HN, Harger G, Markovic N, Roberts JM. Maternal cereal consumption and adequacy of micronutrient intake in the periconceptional period. *Public Health Nutrition*. 2009;12(8):1276-1283. doi:10.1017/S1368980008003881

34. Krieger N, Sidney S. Racial discrimination and blood pressure: the CARDIA Study of young black and white adults. *Am J Public Health*. 1996;86(10):1370-1378. doi:10.2105/AJPH.86.10.1370

35. Connor KM, Davidson JRT. Development of a new resilience scale: The Connor-Davidson Resilience Scale (CD-RISC). *Depression and Anxiety*. 2003;18(2):76-82. doi:10.1002/da.10113

36. Conover CA, Oxvig C. The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story. *Endocrine Reviews*. 2023;44(6):1012-1028. doi:10.1210/endrev/bnad017

37. Chełchowska M, Gajewska J, Mazur J, Ambroszkiewicz J, Maciejewski TM, Leibschang J. Serum pregnancy-associated plasma protein A levels in the first, second and third trimester of pregnancy: relation to newborn anthropometric parameters and maternal tobacco smoking. *Arch Med Sci*. 2016;12(6):1256-1262. doi:10.5114/aoms.2016.62908

38. Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. *Ultrasound in Obstetrics & Gynecology*. 2015;46(1):42-50. doi:10.1002/uog.14870

39. Uriel M, Romero Infante XC, Rincón Franco S, Ibáñez Pinilla EA, Rojas NA. Higher PAPP-A Values in Pregnant Women Complicated with Preeclampsia Than with Gestational Hypertension. *Reprod Sci*. 2023;30(8):2503-2511. doi:10.1007/s43032-023-01176-1

40. Kramer AW, Lamale-Smith LM, Winn VD. Differential expression of human placental PAPP-A2 over gestation and in preeclampsia. *Placenta*. 2016;37:19-25. doi:10.1016/j.placenta.2015.11.004

41. Liu X, Chen L, Li J, et al. Physical Activity and High-Sensitivity C-Reactive Protein in Pregnancy: Does It Matter during Leisure or Work? *Medicine & Science in Sports & Exercise*. 2024;56(1):110. doi:10.1249/MSS.0000000000003287

42. Catov JM, Parker CB, Gibbs BB, et al. Patterns of leisure-time physical activity across pregnancy and adverse pregnancy outcomes. *Int J Behav Nutr Phy*. 2018;15(1):68. doi:10.1186/s12966-018-0701-5

43. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. *Experimental Cell Research*. 2006;312(5):527-537. doi:10.1016/j.yexcr.2005.11.008

44. Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, et al. The role of endoglin and its soluble form in pathogenesis of preeclampsia. *Mol Cell Biochem*. 2022;477(2):479-491. doi:10.1007/s11010-021-04294-z

45. Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, et al. Soluble endoglin concentration in maternal blood as a diagnostic biomarker of preeclampsia: A systematic review and meta-analysis. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2021;258:366-381. doi:10.1016/j.ejogrb.2021.01.039

46. El-Dayem T, Elagwany A, Khamis M, Kamha E, Hassan A. Correlation of serum soluble endoglin to the severity of pre-eclampsia and its effect on the pregnancy outcome. *Int J Reprod Contracept Obstet Gynecol*. Published online 2016:1593-1600. doi:10.18203/2320-1770.ijrcog20161332

47. Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. *American Journal of Obstetrics and Gynecology*. 2011;204(3):244.e1-244.e12. doi:10.1016/j.ajog.2010.10.001

48. Hauspurg A, Marsh DJ, McNeil RB, et al. Association of N-Terminal Pro–Brain Natriuretic Peptide Concentration in Early Pregnancy With Development of Hypertensive

Disorders of Pregnancy and Future Hypertension. *JAMA Cardiology*. 2022;7(3):268-276. doi:10.1001/jamacardio.2021.5617

49. Bhattacharjee J, Mohammad S, Goudreau AD, Adamo KB. Physical activity differentially regulates VEGF, PlGF, and their receptors in the human placenta. *Physiological Reports*. 2021;9(2):e14710. doi:10.14814/phy2.14710

50. Theilen LH, Greenland P, Varagic J, et al. Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: the nuMoM2b Heart Health Study. *Pregnancy Hypertens*. 2022;28:28-34. doi:10.1016/j.preghy.2022.01.012

Table S1. Cardiovascular Health Scoring algorithm for health behaviors in pregnancy. MVPA: moderate-to-vigorous physical activity; HEI: Healthy Eating Index; SBP: systolic blood pressure; DBP: diastolic blood pressure.

	Value	Cardiovascular Health Score
Physical Activity (minutes MVPA/week)	0	0
	1-29	20
	30-59	40
	60-89	60
	90-119	80
	120-149	90
	150+	100
Diet (HEI percentile)	$<25^{th}$	0
	25th-49th	25
	50th-74th	50
	75th-94th	80
	$\geq 95^{th}$	100
Sleep Duration (mean hours/night)	<4	0
	4 - <5	20
	5 - <6 or ≥10	40
	6 - <7	70
	9 - <10	90
	7 - <9	100
Smoking	Current smoking	0
	Smoked within 3 months of conception	25
	Former smoker, quit prior to 3 months before conception	50
	Never smoker	100
	Lives with current smoker	Subtract 20 points unless score already = 0
Blood pressure (mmHg)	≥160 SBP or ≥100 DBP	0
	140-159 SBP or 90-99 DBP	25
	130-139 SBP or 80-89 DBP	50
	120-129 SBP and <80 DBP	75
	<120 SBP and <80 DBP	100
Body Mass Index (kg/m^2)	≥40	0
	35-<40	15
	30-<35	30
	25-<30	70
	<25	100

Table S2. Descriptive characteristics of full versus selected sample. Data presented as mean ± SD or frequency (%). Means, SD, and percentages for the selected sample are weighted by sampling proportion. Hypothesis tests were conducted using t-tests or Chi-square tests, as appropriate. Significance accepted at p<0.05. APO: adverse pregnancy outcome; BMI: body mass index; GED: general education diploma.

	Full sample (N=10,038)	Selected sample (n=2,188)	p-value
Maternal age (years)	26.9 ± 5.67	26.9 ± 5.65	0.88
BMI (kg/m^2)	26.3 ± 6.33	26.0 ± 6.10	**0.02**
Maternal race			**0.01**
Asian	407 (4%)	73 (3%)	
Black non-Hispanic	1418 (14%)	352 (13%)	
Hispanic	1700 (17%)	360 (16%)	
White non-Hispanic	5989 (60%)	1277 (63%)	
Other	514 (5%)	125 (5%)	
Educational Attainment			0.81
Less than high school	816 (8%)	218 (8%)	
Completed high school or GED	1171 (12%)	289 (12%)	
Some college	1948 (19%)	446 (19%)	
Associate or technical degree	1005 (10%)	233 (10%)	
Completed college	2772 (28%)	541 (27%)	
Degree work beyond college	2308 (23%)	460 (24%)	
Percentage of Federal Poverty Level			0.17
<100%	1297 (16%)	298 (15%)	
100-200%	1169 (14%)	255 (13%)	
>200%	5662 (70%)	1164 (72%)	
Insurance payor			**0.001**
Commercial	5239 (53%)	1128 (56%)	
Medicare/Medicaid	2711 (27%)	619 (24%)	
Military/Other	164 (2%)	31 (1%)	
Two or more sources	1576 (16%)	337 (17%)	
None (personal income)	269 (3%)	48 (2%)	
Perceived racial discrimination			**<0.001**
None	7172 (71%)	1621 (76%)	
Moderate	1587 (16%)	397 (17%)	
High	1279 (13%)	170 (7%)	
Resilience	79.3 ± 11.74	79.7 ± 11.84	0.16
APO	1502 (15%)	1349 (16%)	0.27

Table S3. Latent Class metrics. AIC: Akaike's information criterion; BIC: Bayesian information criterion.

Solution comparisons	**AIC**	**BIC**
1 Class Solution	355988.6	356046.3
2 Class Solution	353844.9	353938.7
3 Class Solution	345209.8	345339.6
4 Class Solution	343338.1	343504.0
5 Class Solution	343348.1	343550.1
4 Class Solution Characteristics	**N (%)**	**Posterior probability**
Healthy Behaviors	756 (34.6%)	0.78
Active with Poor Diet	449 (20.5%)	0.73
Inactive with Poor Diet	717 (32.8%)	0.95
Less Healthy Behaviors	265 (12.1%)	0.95
Overall	2188 (100%)	0.85

Table S4. Absolute placental biomarker concentrations in each trimester by latent class. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor

	Healthy Behaviors (n=756)	Active with Poor Diet (n=449)	Inactive with Poor Diet (n=718)	Less Healthy Behaviors (n=265)	p-value
First trimester biomarker concentrations					
PAPP-A (mU/mL)	1035.4 (445.0 – 1887.1)	970.1 (476.6 – 1944.9)	975.5 (446.1 – 1964.0)	946.5 (485.1 – 2055.3)	0.143
VEGF (pg/mL)	0.76 (0.54 – 1.14)	0.79 (0.50 – 1.13)	0.71 (0.50 – 1.06)	0.70 (0.53 – 1.07)	0.845
PlGF (pg/mL)	42.1 (28.1 – 58.1)	42.4 (30.4 – 58.6)	39.8 (29.4 – 56.4)	40.1 (29.7 – 56.8)	0.018
sFlt-1 (pg/mL)	915.8 (693.7 – 1179.5)	944.8 (688.6 – 1180.8)	925.2 (726.8 – 1181.0)	951.8 (704.4 – 1340.1)	0.613
sEng (ng/mL)	6.46 (5.55 – 7.61)	6.29 (5.30 – 7.23)	6.32 (5.31 – 7.46)	6.12 (5.28 – 7.27)	**<0.001**
Second trimester biomarker concentrations					
PAPP-A (mU/mL)	9021.2 (5089.7 – 14055.1)	8376.3 (5210.4 – 13740.4)	9830.2 (5924.4 – 15858.1)	10820.6 (6518.0 – 15402.5)	0.034
VEGF (pg/mL)	0.95 (0.64 – 1.54)	0.95 (0.63 – 1.81)	0.89 (0.65 – 1.38)	0.89 (0.68 – 1.31)	0.432
PlGF (pg/mL)	190.8 (13223 – 269.3)	191.6 (129.4 – 283.4)	192.1 (133.3 – 286.8)	203.4 (126.7 – 295.8)	**0.003**
sFlt-1 (pg/mL)	890.7 (628.4 – 1156.8)	843.6 (631.1 – 1209.8)	900.3 (675.1 – 1278.2)	963.1 (684.8 – 1378.9)	0.194
sEng (ng/mL)	5.42 (4.73 – 6.19)	5.24 (4.62 – 6.10)	5.36 (4.60 – 6.24)	5.29 (4.57 – 6.41)	0.033

Table S5. Adjusted marginal means (95% confidence intervals) between latent classes and 1st trimester placental analytes. Model 1 adjusted for gestational age at blood draw. Model 2 additionally adjusted for maternal age, race, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

	Model 1	p-value	Model 2	p-value
Log PAPP-A (mU/mL)				
Healthy Behaviors	2.90 (2.86, 2.95)	Reference	2.88 (2.83, 2.92)	Reference
Active with Poor Diet	2.88 (2.82, 2.94)	0.613	2.90 (2.83, 2.96)	0.621
Inactive with Poor Diet	2.92 (2.88, 2.96)	0.459	2.93 (2.88, 2.97)	0.137
Less Healthy Behaviors	2.92 (2.83, 3.00)	0.765	2.86 (2.75, 2.97)	0.818
Log VEGF (pg/mL)				
Healthy Behaviors	-0.09 (-0.13, -0.05)	Reference	-0.07 (-0.11, -0.03)	Reference
Active with Poor Diet	-0.09 (-0.15, -0.03)	0.967	-0.14 (-0.20, -0.08)	0.037
Inactive with Poor Diet	-0.12 (-0.17, -0.08)	0.269	-0.15 (-0.19, -0.10)	0.013
Less Healthy Behaviors	-0.11 (-0.18, -0.04)	0.665	-0.09 (-0.18, 0.002)	0.647
Log PlGF (pg/mL)				
Healthy Behaviors	1.60 (1.57, 1.62)	Reference	1.61 (1.58, 1.63)	Reference
Active with Poor Diet	1.62 (1.59, 1.65)	0.190	1.62 (1.58, 1.65)	0.682
Inactive with Poor Diet	1.60 (1.58, 1.63)	0.745	1.58 (1.55, 1.62)	0.333
Less Healthy Behaviors	1.62 (1.59, 1.66)	0.239	1.57 (1.53, 1.61)	0.187
Log sFlt-1 (pg/mL)				
Healthy Behaviors	2.95 (2.94, 2.97)	Reference	2.95 (2.93, 2.96)	Reference
Active with Poor Diet	2.95 (2.93, 2.98)	0.908	2.97 (2.94, 2.99)	0.233
Inactive with Poor Diet	2.97 (2.95, 2.99)	0.304	**2.98 (2.96, 3.00)**	**0.008**
Less Healthy Behaviors	2.98 (2.95, 3.02)	0.159	2.95 (2.90, 3.00)	0.883
sEng (ng/mL)				
Healthy Behaviors	6.69 (6.54, 6.84)	Reference	6.57 (6.43, 6.72)	Reference
Active with Poor Diet	6.42 (6.21, 6.62)	0.036	6.55 (6.33, 6.76)	0.839
Inactive with Poor Diet	6.54 (6.37, 6.70)	0.179	6.66 (6.48, 6.84)	0.463
Less Healthy Behaviors	6.36 (6.08, 6.63)	0.035	6.46 (6.13, 6.79)	0.520

Table S6. Adjusted marginal means (95% confidence intervals) between latent classes and 2nd trimester placental analytes. Model 1 adjusted for gestational age at blood draw and 1st trimester analyte concentration. Model 2 additionally adjusted for maternal age, race, body mass index, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

	Adjusted Marginal Mean (95% CI) Model 1	**p-value**	**Adjusted Marginal Mean (95% CI) Model 2**	**p-value**
Log PAPP-A (mU/mL)				
Healthy Behaviors	3.92 (3.90, 3.95)	Reference	3.91 (3.88, 3.93)	Reference
Active with Poor Diet	3.93 (3.89, 3.96)	0.809	3.92 (3.89, 3.96)	0.564
Inactive with Poor Diet	3.96 (3.94, 3.99)	0.022	3.95 (3.93, 3.98)	0.024
Less Healthy Behaviors	3.98 (3.93, 4.02)	0.025	3.98 (3.93, 4.03)	0.021
Log VEGF (pg/mL)				
Healthy Behaviors	0.02 (-0.01, 0.05)	Reference	0.02 (-0.01, 0.05)	Reference
Active with Poor Diet	0.05 (0.01, 0.09)	0.329	0.05 (-0.001, 0.09)	0.360
Inactive with Poor Diet	0.03 (-0.001, 0.06)	0.803	0.03 (-0.01, 0.07)	0.743
Less Healthy Behaviors	0.01 (-0.04, 0.07)	0.731	-0.01 (-0.07, 0.07)	0.553
Log PlGF (pg/mL)				
Healthy Behaviors	2.26 (2.23, 2.29)	Reference	2.24 (2.20, 2.27)	Reference
Active with Poor Diet	2.26 (2.22, 2.30)	0.987	2.24 (2.19, 2.29)	0.860
Inactive with Poor Diet	2.26 (2.23, 2.29)	0.819	2.26 (2.23, 2.30)	0.216
Less Healthy Behaviors	2.27 (2.23, 2.30)	0.729	2.24 (2.20, 2.28)	0.909
Log sFlt-1 (pg/mL)				
Healthy Behaviors	2.94 (2.93, 2.96)	Reference	2.95 (2.93, 2.96)	Reference
Active with Poor Diet	2.94 (2.93, 2.96)	0.934	2.94 (2.92, 2.96)	0.610
Inactive with Poor Diet	2.96 (2.94, 2.97)	0.214	2.95 (2.94, 2.97)	0.569
Less Healthy Behaviors	2.94 (2.92, 2.97)	0.990	2.95 (2.92, 2.99)	0.830
sEng (ng/mL)				
Healthy Behaviors	5.52 (5.43, 5.60)	Reference	5.57 (5.48, 5.66)	Reference
Active with Poor Diet	5.60 (5.49, 5.71)	0.228	5.61 (5.48, 5.74)	0.642
Inactive with Poor Diet	5.58 (5.49, 5.67)	0.279	5.64 (5.52, 5.75)	0.404
Less Healthy Behaviors	5.64 (5.47, 5.82)	0.190	5.70 (5.51, 5.89)	0.257

Table S7. Association between 1st trimester component score and placental biomarkers in the 1st and 2nd trimesters. ß coefficients are per 10-point increase in component score. Model 1 is adjusted for gestational age at the blood draw (1st and 2nd trimester analyses) and 1st trimester biomarker concentration (2nd trimester analyses only). Model 2 is additionally adjusted for maternal age, race, body mass index, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

	ß coefficient (95% CI) Model 1	**p-value**	**ß coefficient (95% CI) Model 2**	**p-value**
First trimester biomarkers				
Log PAPP-A (mU/mL)				
Smoking	-0.0002 (-0.0084, 0.0080)	0.956	-0.0002 (-0.0096, 0.0092)	0.964
Diet	-0.003 (-0.011, 0.006)	0.561	-0.004 (-0.015, 0.008)	0.506
Sleep	0.002 (-0.012, 0.016)	0.788	0.005 (-0.011, 0.021)	0.559
Log VEGF (pg/mL)				
Smoking	-0.004 (-0.011, 0.003)	0.280	0.002 (-0.006, 0.009)	0.668
Diet	-0.0003 (-0.0082, 0.0075)	0.933	0.008 (-0.002, 0.017)	0.118
Sleep	-0.003 (-0.016, 0.009)	0.597	-0.007 (-0.022, 0.008)	0.341
Log PlGF (pg/mL)				
Smoking	**-0.006 (-0.010, -0.002)**	**0.004**	-0.006 (-0.010, -0.0001)	0.018
Diet	-0.0046 (-0.0092, -0.0001)	0.046	0.0008 (-0.0048, 0.0065)	0.772
Sleep	-0.002 (-0.008, 0.004)	0.559	0.004 (-0.003, 0.011)	0.317
Log sFlt-1 (pg/mL)				
Smoking	0.001 (-0.002, 0.004)	0.392	-0.0004 (-0.004, 0.003)	0.837
Diet	-0.0006 (-0.0042, 0.0029)	0.729	-0.003 (-0.007, 0.001)	0.188
Sleep	-0.002 (-0.007, 0.004)	0.506	0.001 (-0.006, 0.009)	0.691
sEng (ng/mL)				
Smoking	**0.050 (0.024, 0.076)**	**<0.001**	0.035 (0.008, 0.062)	0.011
Diet	0.034 (0.004, 0.063)	0.026	0.014 (-0.019 0.046)	0.416
Sleep	**0.064 (0.020, 0.11)**	**0.004**	0.046 (-0.005, 0.097)	0.075
Second trimester biomarkers				
Log PAPP-A (mU/mL)				
Smoking	0.0045 (0.0001, 0.0088)	0.044	0.0043 (-0.0006, 0.0093)	0.088
Diet	-0.0027 (-0.0077, 0.0023)	0.284	-0.0016 (-0.0072, 0.0039)	0.561
Sleep	-0.0045 (-0.0121, 0.0031)	0.243	-0.0040 (-0.0128, 0.0056)	0.442
Log VEGF (pg/mL)				
Smoking	-0.0004 (-0.0060, 0.0051)	0.877	0.0006 (-0.0060, 0.0073)	0.849
Diet	-0.0017 (-0.0076, 0.0041)	0.556	-0.0001 (-0.0069, 0.0066)	0.975
Sleep	0.0019 (-0.0074, 0.0111)	0.691	0.0055 (-0.0060, 0.0169)	0.351
Log PlGF (pg/mL)				
Smoking	0.0004 (-0.0044, 0.0053)	0.858	0.0030 (-0.0029, 0.0089)	0.323
Diet	0.0007 (-0.0058, 0.0072)	0.828	-0.0015 (-0.0010, 0.0071)	0.732
Sleep	-0.0027 (-0.0094, 0.0040)	0.427	-0.0001 (-0.0075, 0.0074)	0.983

Log sFlt-1 (pg/mL)				
Smoking	0.0002 (-0.0020, 0.0025)	0.860	0.0011 (-0.0016, 0.0037)	0.430
Diet	-0.0012 (-0.0037, 0.0013)	0.347	0.0003 (-0.0029, 0.0035)	0.849
Sleep	-0.0004 (-0.0044, 0.0036)	0.853	-0.0006 (-0.0055, 0.0044)	0.823
sEng (ng/mL)				
Smoking	-0.0069 (-0.0220, 0.0080)	0.362	0.0049 (-0.0128, 0.0227)	0.590
Diet	-0.0041 (-0.0220, 0.0139)	0.658	-0.0013 (-0.0252, 0.0227)	0.917
Sleep	-0.011 (-0.039, 0.017)	0.441	-0.0070 (-0.0379, 0.0240)	0.659

Table S8. Adjusted marginal means (95% confidence intervals) between physical activity categories and 1st and 2nd trimester placental analytes. Physical activity categories defined as: None = 0 minutes/week; Insufficient = 1-149 minutes/week; Sufficient = 150-299 minutes/week; High = ≥300 minutes per week. Model 1 adjusted for gestational age at blood draw and 1st trimester analyte concentration. Model 2 additionally adjusted for maternal age, race, body mass index, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

	Adjusted Marginal Mean (95% CI) Model 1	**p-value**	**Adjusted Marginal Mean (95% CI) Model 2**	**p-value**
First trimester biomarkers				
Log PAPP-A (mU/mL)				
None	2.91 (2.87, 2.96)	Reference	2.92 (2.86, 2.97)	Reference
Insufficient	2.92 (2.88, 2.96)	0.822	2.93 (2.88, 2.97)	0.813
Sufficient	2.96 (2.91, 3.01)	0.177	2.93 (2.88, 2.99)	0.727
High	2.84 (2.77, 2.92)	0.130	2.81 (2.72, 2.89)	0.040
Log VEGF (pg/mL)				
None	-0.14 (-0.18, -0.10)	Reference	-0.19 (-0.23, -0.14)	Reference
Insufficient	-0.09 (-0.14, -0.05)	0.115	**-0.08 (-0.13, -0.03)**	**0.002**
Sufficient	-0.13 (-0.18, -0.08)	0.731	-0.11 (-0.16, -0.06)	0.039
High	-0.06 (-0.12, 0.002)	0.041	**-0.06 (-0.12, 0.01)**	**0.002**
Log PlGF (pg/mL)				
None	1.60 (1.58, 1.63)	Reference	1.58 (1.54, 1.61)	Reference
Insufficient	1.61 (1.59, 1.64)	0.580	1.61 (1.58, 1.64)	0.157
Sufficient	1.61 (1.58, 1.64)	0.649	1.61 (1.57, 1.65)	0.220
High	1.60 (1.57, 1.63)	0.982	1.61 (1.58, 1.64)	0.219
Log sFlt-1 (pg/mL)				
None	2.96 (2.94, 2.98)	Reference	2.98 (2.96, 3.00)	Reference
Insufficient	2.97 (2.95, 2.99)	0.478	2.97 (2.95, 2.99)	0.669
Sufficient	2.97 (2.95, 3.00)	0.475	2.97 (2.95, 3.00)	0.706
High	2.94 (2.91, 2.96)	0.117	**2.92 (2.90, 2.95)**	**0.003**
sEng (ng/mL)				
None	6.45 (6.28, 6.62)	Reference	6.60 (6.40, 6.79)	Reference
Insufficient	6.60 (6.43, 6.78)	0.225	6.65 (6.48, 6.82)	0.655
Sufficient	6.59 (6.38, 6.79)	0.322	6.48 (6.27, 6.70)	0.438
High	6.61 (6.39, 6.83)	0.251	6.58 (6.35, 6.80)	0.904
Second trimester biomarkers				
Log PAPP-A (mU/mL)				
None	3.98 (3.95, 4.00)	Reference	3.98 (3.95, 4.01)	Reference
Insufficient	3.92 (3.90, 3.95)	**0.005**	**3.92 (3.89, 3.94)**	**0.003**
Sufficient	3.93 (3.89, 3.96)	0.022	**3.92 (3.89, 3.95)**	**0.006**
High	3.94 (3.91, 3.97)	0.081	**3.91 (3.88, 3.95)**	**0.008**
Log VEGF (pg/mL)				
None	0.02 (-0.01, 0.05)	Reference	0.009 (-0.029, 0.048)	Reference

Insufficient	0.02 (-0.01, 0.05)	0.982	0.01 (-0.02, 0.05)	0.879
Sufficient	0.04 (0.004, 0.081)	0.403	0.044 (-0.001, 0.089)	0.253
High	0.02 (-0.02, 0.06)	0.858	0.02 (-0.03, 0.06)	0.813
Log PlGF (pg/mL)				
None	2.27 (2.23, 2.30)	Reference	2.28 (2.24, 2.32)	Reference
Insufficient	2.25 (2.22, 2.28)	0.558	2.24 (2.21, 2.71)	0.159
Sufficient	2.27 (2.23, 2.31)	0.856	2.25 (2.20, 2.30)	0.454
High	2.26 (2.22, 2.30)	0.783	2.23 (2.18, 2.27)	0.129
Log sFlt-1 (pg/mL)				
None	2.96 (2.95, 2.97)	Reference	2.97 (2.95, 2.98)	Reference
Insufficient	2.94 (2.92, 2.95)	0.031	2.94 (2.92, 2.95)	0.011
Sufficient	2.94 (2.93, 2.96)	0.092	2.95 (2.93, 2.97)	0.216
High	2.95 (2.93, 2.97)	0.533	2.95 (2.93, 2.97)	0.258
sEng (ng/mL)				
None	5.51 (5.42, 5.60)	Reference	5.57 (5.46, 5.68)	Reference
Insufficient	5.62 (5.52, 5.73)	0.100	5.67 (5.56, 5.79)	0.215
Sufficient	5.55 (5.44, 5.66)	0.585	5.59 (5.46, 5.71)	0.855
High	5.58 (5.46, 5.70)	0.351	5.57 (5.45, 5.69)	0.996